

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant(s): Evert Johannes Bunschoten, et al.  
App. No.: 10/517,028  
Filing Date: June 6, 2003  
Title: METHOD OF CONTROLLED OVARIAN  
HYPERSTIMULATION AND  
PHARMACEUTICAL KIT FOR USE IN  
SUCH METHOD  
Art Unit: TBD  
Examiner: TBD

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date:

06/13/05

Date

  
Teddy C. Scott, Jr., Ph.D.  
Registration No. 53,573

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 AND 1.98

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Form PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08B be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of a first Office Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b)(3).


No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey Simon Arnold & White, LLP Deposit Account 08-3038.

Respectfully submitted,

HOWREY LLP

Dated: June 13, 2005

By:

  
Teddy C. Scott, Jr., Ph.D.  
Registration No.: 53,573  
Customer No.: 22930

HOWREY LLP  
321 N. Clark Street, Suite 3400  
Chicago, IL 60661  
(312) 595-1239 (main)  
(312) 846-5621 (direct)  
(312) 595-2250 (fax)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/517,028
				<b>Filing Date</b>	June 6, 2003
				<b>First Named Inventor</b>	Evert Johannes Bunschoten
				<b>Group Art Unit</b>	TBD
				<b>Examiner Name</b>	TBD
<b>Sheet</b>	1	of	2	<b>Attorney Docket Number</b>	05558.0025.PCUS00

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
	C2	Al-Inany, H., et al., "GnRH Antagonist in Assisted Reproduction: a Cochrane Review," Human Reproduction, Vol. 17, No. 4, pp. 874-885 (2002)	
	C3	Belaisch-Allart, J., et al., "Recommendations of Good Practice: Medicines that Induce Ovulation," Gynecologie Obsterique & Fertilité, Vol. 31, pp. 678-686 (June 2003)	
	C4	Burgues, S., et al., "The Effectiveness and Safety of Recombinant Human LH to Support Follicular Development Induced by Recombinant Human FSH in WHO Group I Anovulation: Evidence from a Multicentre Study in Spain," Human Reproduction, Vol. 16, No. 12, pp. 2525-2532 (2001)	
	C5	Fausser, B., et al., "Endocrine Profiles after Triggering of Final Oocyte Maturation with GnRH Agonist after Cotreatment with the GnRH Antagonist Ganirelix during Ovarian Hyperstimulation for <i>in vitro</i> Fertilization," The Journal of Clinical Endocrinology and Metabolism, Vol. 87, No. 2, pp. 709-715 (2002)	
	C6	Hugues, J., et al., "Les Protocoles de Stimulation Ovarienne en vue de Fecondation <i>in vitro</i> : Evolution au cours des Dernieres Annees. Qu'en est-il en 2003? (Evolution of Protocoles for Ovarian Stimulation <i>in vitro</i> Fertilization in the Past Years : What's in Store in 2003?)" Mt. Endocrinologie et Reproduction, Vol. 5, No. 1, pp. 7-17, (2003)	
	C7	Just, A., et al., "Die Ovarielle Stimulation Und Ovulationsinduktion In Der Assistierten Reproduktion," Journal Fertil Reprod., Vol. 12, No. 4, pp. 20, 22, and 24 (2002)	
	C8	Krusche, C., et al., "The Progesterone Antagonist Onapristone Retards the Advanced Endometrial Transformation after Gonadotropin Stimulation in Rabbits," Steroids, Vol. 65, pp. 773-782 (2000)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/517,028
				Filing Date	June 6, 2003
				First Named Inventor	Evert Johannes Bunschoten
				Group Art Unit	TBD
				Examiner Name	TBD
Sheet	2	of	2	Attorney Docket Number	05558.0025.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
	C9	Lisi, F., et al., "Use of Recombinant Follicle-Stimulating Hormone (Gonal F) and Recombinant Luteinizing Hormone (Luvris) for Multiple Follicular Stimulation in Patients with a Suboptimal Response to <i>in vitro</i> Fertilization," Fertility and Sterility, Vol. 79, No. 4, pp. 1037-1038 (April 2003)	
	C10	Ludwig, M., et al., "Developments in Drugs for Ovarian Stimulation," Best Practice & Research Clinical Obstetrics & Gynaecology, Vol. 17, No. 2, pp. 231-247 (2003)	
	C11	Ludwig, M., et al., "Moderne Aspekte der Reproduktionsmedizin (Modern Aspects of Reproduction Medicine)," Gynakologe 2002 Germany, Vol. 35., No. 9, pp. 861-866 (2002)	
	C12	Ron-El, R., et al., "Induction of Ovulation after GnRH Antagonists," Human Reproduction Update 2000, <i>European Society of Human Reproduction and Embrology</i> , Vol. 6, No. 4, pp. 318-321 (2000)	
	C13	Wikland, M., et al., "A Prospective, Randomized Comparison of Two Starting Doses of Recombinant FSH in Combination with Cetrorelix in Women Undergoing Ovarian Stimulation for IVF/ICSI," Human Reproduction, <i>European Society of Human Reproduction and Embrology</i> , Vol. 16, No. 8, pp. 1676-1681 (2001)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.